{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:13:31Z","timestamp":1761664411045,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.reuma.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T08:55:43Z","timestamp":1545900943000},"page":"396-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Seguridad y supervivencia de las terapias biol\u00f3gicas: primer informe del registro paraguayo-uruguayo de acontecimientos adversos con terapias biol\u00f3gicas Biobadaguay"],"prefix":"10.1016","volume":"16","author":[{"given":"Paloma","family":"de Abreu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"\u00c1vila-Pedretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoilo","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Isabel","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Cabrera-Villalba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Melgarejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Delgadillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Gabriel","family":"Elizaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darwin Octavio","family":"Cordovilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Palleiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Mazzoleni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2018.08.009_bib0140","first-page":"279","article-title":"2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis","volume":"11","author":"Sanmarti","year":"2015","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.08.009_bib0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol."},{"key":"10.1016\/j.reuma.2018.08.009_bib0150","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther."},{"key":"10.1016\/j.reuma.2018.08.009_bib0155","first-page":"193","article-title":"Methods to analyze real-world databases and registries","volume":"67","author":"Kremers","year":"2009","journal-title":"Bull NYU Hosp Jt Dis."},{"key":"10.1016\/j.reuma.2018.08.009_bib0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","article-title":"A comparison of patient characteristics and outcomes in selected European and nd U.S. rheumatoid arthritis registries","volume":"40","author":"Curtis","year":"2010","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.08.009_bib0165","first-page":"189","article-title":"Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0","volume":"8","author":"Ventura-Rios","year":"2012","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.08.009_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","article-title":"Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results","volume":"51","author":"Titton","year":"2011","journal-title":"Rev Bras Reumatol."},{"key":"10.1016\/j.reuma.2018.08.009_bib0175","first-page":"14","article-title":"Caracter\u00edsticas de los tratamientos biol\u00f3gicos en enfermedades reum\u00e1ticas en Argentina: quinto informe del registro Biobadasar","volume":"27","author":"De la Vega","year":"2016","journal-title":"Rev Arg Reumatol."},{"key":"10.1016\/j.reuma.2018.08.009_bib0180","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients","volume":"61","author":"Charlson","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.reuma.2018.08.009_bib0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.reuma.2018.08.009_bib0190","unstructured":"Informe Biobadaser fase III. 2016 [consultado Dic 2016]. Disponible en: https:\/\/biobadaser.ser.es."},{"issue":"Suppl 1","key":"10.1016\/j.reuma.2018.08.009_bib0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.reuma.2008.11.007","article-title":"Update of Biobadaser","volume":"5","author":"Carmona","year":"2009","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.08.009_bib0200","first-page":"1","article-title":"Safety of biologics in rheumatoid arthritis: Data from randomized controlled trials and registries","volume":"9","author":"Codreanu","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.reuma.2018.08.009_bib0205","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: A network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database System Rev."},{"key":"10.1016\/j.reuma.2018.08.009_bib0210","first-page":"08","article-title":"Tercer reporte de eventos adversos con tratamientos biol\u00f3gicos en Argentina. Informe de registro Biobadasar","volume":"24","author":"De la Vega","year":"2013","journal-title":"Rev Arg Reumatol."},{"key":"10.1016\/j.reuma.2018.08.009_bib0215","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2011-200302","article-title":"Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the Spanish registry Biobadaser 2.0","volume":"71","author":"Gomez-Reino","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.08.009_bib0220","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry Biobadaser","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2018.08.009_bib0225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2018.08.009_bib0230","first-page":"1","article-title":"Factors associated with withdrawal of the anti-TNFalpha biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry","volume":"17","author":"Mok","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reuma.2018.08.009_bib0235","first-page":"2433","article-title":"Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients","volume":"33","author":"Duclos","year":"2006","journal-title":"J Rheum"},{"key":"10.1016\/j.reuma.2018.08.009_bib0240","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.08.009_bib0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","article-title":"Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival","volume":"43","author":"Flouri","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.08.009_bib0250","first-page":"396","article-title":"Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis","volume":"36","author":"Machado-Alba","year":"2014","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.reuma.2018.08.009_bib0255","first-page":"27","article-title":"Infecciones en pacientes con artritis reumatoide: medicamentos moduladores de la respuesta biol\u00f3gica versus f\u00e1rmacos modificadores de la enfermedad. Seguimiento a un a\u00f1o","volume":"21","author":"Vega Miranda","year":"2014","journal-title":"Rev Colomb Reumatol."},{"key":"10.1016\/j.reuma.2018.08.009_bib0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","article-title":"Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: Results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry","volume":"17","author":"Sakai","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2018.08.009_bib0265","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"Van Dartel","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.08.009_bib0270","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12891-015-0805-x","article-title":"The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment","volume":"16","author":"Macfarlane","year":"2015","journal-title":"BMC Musculoskelet Disord."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1830189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1830189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:59:55Z","timestamp":1761663595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X1830189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1699258X1830189X"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2018.08.009","relation":{},"ISSN":["1699-258X"],"issn-type":[{"type":"print","value":"1699-258X"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seguridad y supervivencia de las terapias biol\u00f3gicas: primer informe del registro paraguayo-uruguayo de acontecimientos adversos con terapias biol\u00f3gicas Biobadaguay","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}